Clinical Trial

Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a phase II, open label clinical trial determining efficacy of Fianlimab in combination with Cemiplimab in subjects with Melanoma. These are subjects who will have surgery to remove their cancer.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2026-04-07; most recent amendment 2026-06-03.
Trial Details
NCT Number NCT07527325
Lead Sponsor University of California, Irvine
Collaborators: UC Cancer Consortium
Conditions Melanoma (Skin)
Enrollment 35 participants
Start Date 2026-07-01
Primary Completion 2029-02-01 (estimated)
Study Completion 2030-02-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-05